Form 4: KalVista Pharmaceuticals Director Acquires 17,000 Stock Options

KalVista Pharmaceuticals director, Laurence Reid, acquired 17,000 stock options with a strike price of $10.07, vesting over 36 months.

Summary

• Laurence Reid, a director at KalVista Pharmaceuticals, acquired 17,000 stock options on November 23, 2024.
• The options have an exercise price of $10.07 per share.
• The options vest over a 36-month period, with the first 1/36th vesting on December 25, 2024, and the remaining vesting monthly thereafter, contingent on continued service.
• The options expire on November 22, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction, indicating confidence from a director, which is generally positive, but not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard transaction for a director of a public company, often used as part of their compensation package and to align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the pharmaceutical industry, aligning their interests with the long-term success of the company.
• The vesting schedule of 36 months is also typical for such grants, encouraging long-term commitment from the director.
• The exercise price of $10.07 is a standard feature of stock options, allowing the director to benefit from future share price appreciation.

Stakeholder Impact

• The stock option grant could positively impact shareholder sentiment, as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, KalVista Pharmaceuticals, director, insider trading, equity, vesting